Anemia and Other Blood Disorder Drugs Market Report 2025

This Anemia and Other Blood Disorder Drugs market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The anemia and other blood disorder drugs market size has grown strongly in recent years. It will grow from $11.61 billion in 2024 to $12.38 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to disease prevalence, global health initiatives, aging population, pharmaceutical innovation, patient awareness.

The anemia and other blood disorder drugs market size is expected to see strong growth in the next few years. It will grow to $16.09 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to emerging markets, global demographics, economic factors. Major trends in the forecast period include research and development, technological advances, biologics and targeted therapies, gene therapies, telemedicine and remote monitoring, orphan drug designations, mergers and acquisitions.

The rising prevalence of anemia worldwide is a significant driver for the market. Unhealthy lifestyles, shifting dietary patterns, and heightened stress levels have led to an increase in anemia cases across the globe. As an example, anemia has become a common health issue in the elderly population, with a prevalence rate of approximately 17% among those aged over 65. The World Bank has reported that anemia ranks as the 8th most prevalent disease among women and young individuals. This increase in anemia prevalence contributes to the growth of the market for anemia and other blood disorder drugs.

The increasing demand for personalized medicine is expected to drive the growth of the anemia and other blood disorder drugs market. Personalized medicine involves using an individual's genetic profile to make decisions regarding disease prevention, diagnosis, and treatment. This approach offers more effective and precisely targeted therapies for anemia and other blood disorders, leading to better and longer-lasting patient health outcomes, making medical treatment more efficient and effective. For example, in March 2023, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022, and around 12 of these therapeutic NMEs are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Therefore, the increasing demand for personalized medicine is fueling the growth of the anemia and other blood disorder drugs market.

The growing utilization of biologics for the treatment of anemia and other blood disorders has become a prominent trend. Biologics are substances made from proteins, sugars, nucleic acids, or a combination of these components, often derived from living organisms like humans, animals, or microorganisms, and may contain living organism components. This increasing preference for biologics over traditional drugs has led to a reduced number of drugs used in treating anemia and other blood disorders, impacting the market. For instance, Hospira, a medical device and pharmaceutical company, submitted its initial biologics license application to the FDA for a drug designed to treat anemia. Furthermore, the FDA approved the first Epoetin Alfa biosimilar for anemia treatment associated with chronic kidney disease, chemotherapy, or the use of zidovudine in patients with HIV infection. The growing adoption of biologics is expected to hinder the growth of the anemia and other blood disorder drugs market.

Companies operating in the anemia and other blood disorder drugs market are increasingly engaging in collaborative efforts with government agencies to jointly develop and commercialize specific drugs. These collaborations involve the sharing of knowledge, technology, and costs, providing a platform for addressing challenges such as expiring licenses and navigating a stringent regulatory environment. For instance, in March 2023, Disc Medicine initiated a collaboration with the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI) for Phase 1/2 and Phase 2 clinical trials of biopterin in adult patients with Diamond-Blackfan Anemia (DBA) and iron deficiency anemia. These studies will be conducted and funded by the NIH through a cooperative research and development agreement (CRADA).

Leading companies in the anemia and other blood disorder drugs market are intensifying their efforts to introduce innovative medications, gaining a competitive advantage in the industry. These novel medications represent significant advancements or new approaches to treating medical conditions and diseases. For example, in August 2023, Bristol-Myers Squibb Company, a prominent US-based pharmaceutical firm, secured approval from the United States Food and Drug Administration (FDA) for Reblozyl as the first-line treatment for anemia in adults with lower-risk myelodysplastic syndromes. Reblozyl stands out as the first therapy to demonstrate its superiority compared to erythropoiesis-stimulating agents (ESAs) in treating MDS-related anemia, as evidenced by interim results from the pivotal Phase 3 COMMANDS study. The approval was based on data from the COMMANDS study, a global Phase 3 trial showing that nearly twice as many Reblozyl-treated patients achieved transfusion independence of at least 12 weeks, along with a concurrent hemoglobin increase when compared to Epoetin alfa.

Anemia and Other Blood Disorder Drugs encompass pharmaceuticals used for the treatment of anemia and related blood disorders. These conditions typically arise when medications trigger the body's immune system to erroneously attack its own red blood cells, leading to hemolysis, a process in which red blood cells prematurely break down.

The primary categories of drugs for anemia and other blood disorders include those for iron deficiency anemia, chronic kidney disease-related anemia, sickle cell anemia, and aplastic anemia. Iron deficiency anemia, a prevalent form of anemia, occurs when the blood lacks a sufficient number of healthy red blood cells responsible for transporting oxygen to the body's cells. Anemia can be further classified into microcytic (low MCV), normocytic (normal MCV), and macrocytic (high MCV) types. These drugs are administered through various methods, including oral and injectable, and are distributed through channels such as hospital pharmacies, online pharmacies, and traditional retail pharmacies.

The anemia and other blood disorder drugs market research report are one of a series of new reports that provides anemia and other blood disorder drugs market statistics, including anemia and other blood disorder drugs industry global market size, regional shares, competitors with anemia and other blood disorder drugs market share, detailed anemia and other blood disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anemia and other blood disorder drugs industry. This anemia and other blood disorder drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

In October 2022, Pfizer, a renowned pharmaceutical company based in the United States, acquired Global Blood Therapeutics Inc. for an undisclosed sum. This strategic acquisition enabled Pfizer to enhance its drug development portfolio and offer several promising best-in-class treatments to individuals suffering from sickle cell disease. Global Blood Therapeutics Inc. is a US-based biotechnology company specializing in the field of anemia and other blood disorder drugs.

Major companies operating in the anemia and other blood disorder drugs market include Amgen Inc., GlaxoSmithKline PLC, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., GlycoMimetics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Pieris Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., Allergan U.S. Inc., Meda Consumer Healthcare Inc., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Galenica Ltd., Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., uniQure N.V., Rubius Therapeutics Inc., BioMarin Pharmaceutical Inc., Grifols S.A., Orchard Therapeutics plc.

North America was the largest region in the anemia and other blood disorder drugs market in 2024. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anemia and other blood disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anemia and other blood disorder drugs market consists of sales of folate analogues, multivitamin and mineral supplements, iron supplements, and erythropoiesis-stimulating agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.